

LIST OF TABLES

Table No.	Description	Page No.
2-1	Details of guidelines for CINV treatment	24
2-2	Drug profiles	25
2-3	Clinical trial details of Amisulpride	27
2-4	Clinical trial details of Granisetron	30
2-5	List of approved polymeric microsphere based LAF's	33
2-6	Literature review of microsphere's-based Drug delivery systems	35
2-7	Examples of IVRT testing methods	40
2-8	Methods Used to Predict Human Plasma Volume of Distribution	44
2-9	Methods Used to Predict Human Plasma Clearance	47
2-10	Literature review of Wajima-Dedrick plot method	51
2-11	In-silico model details from literature	52
3-1	Methods for calculation of clearance	70
3-2	Calculated clearance for human	70
3-3	Methods for calculation of volume of distribution	71
3-4	Calculated volume of distribution for human	71
3-5	Input data for PBPK modelling of Amisulpride	76
3-6	Input data for PBPK modelling of Granisetron	79
3-7	Parameters selected for Parameter sensitivity analysis	82
3-8	Model Validation summary for Amisulpride	89
3-9	Model validation summary for Granisetron	89
3-10	Dosage regimen for Amisulpride and Granisetron	93
3-11	Calculated Drug release as per model 1 (Equation 3-9)	96
3-12	Calculated Drug release as per model 2 (Equation 3-10)	97
3-13	Marketed formulations of Amisulpride and Granisetron	97
4-1	Organoleptic characteristics of drugs	102
4-2	Solubility data	103
4-3	Characteristic FTIR peaks and corresponding functional groups	107
5-1	List of chemicals and reagents	112
5-2	Instrument List	113
5-3	Gradient HPLC programme details	117

Table No.	Description	Page No.
5-4	Calibration data of Amisulpride in 0.1N HCl at initial	120
5-5	Calibration data of Amisulpride in 0.1N HCl after 24 hours	121
5-6	Intraday and Interday precision for amisulpride	122
5-7	Accuracy of UV method for Amisulpride	122
5-8	Calibration data of Granisetron in 0.1N HCl at Initial	123
5-9	Calibration data of Granisetron in 0.1N HCl after 24 hours	123
5-10	Intraday and Interday precision for granisetron	124
5-11	Accuracy of UV method for Granisetron	124
5-12	Calibration data of Amisulpride and Granisetron at Initial	127
5-13	Calibration data of Amisulpride and Granisetron after 24 hours	128
5-14	Intraday and Interday precision for HPLC method	129
5-15	Accuracy evaluation of HPLC method for Amisulpride and Granisetron	129
6-1	Quality target Product profile (QTPP)	133
6-2	Critical Quality Attributes (CQA)	134
6-3	Risk ranking system	136
6-4	Initial risk assessment of Formulation variables	136
6-5	Justification for Selected Formulation Variables	136
6-6	Initial risk assessment of Process variables	137
6-7	Justification for Selected Process Variables	137
6-8	Factors selected for Screening design	141
6-9	Trial summary for screening design	142
6-10	Significance of parameters on responses and model summary for screening design	143
6-11	Screening design summary for Particle size (D90)	146
6-12	Screening design summary for Entrapment efficiency of Amisulpride	151
6-13	Screening design summary for Entrapment efficiency of Granisetron	152
6-14	Screening design summary for Drug loading of Amisulpride	157
6-15	Screening design summary for Drug loading of Granisetron	158

Table No.	Description	Page No.
6-16	Trial summary for confirmatory trials	161
6-17	Significance of parameters on responses and model summary for confirmatory trials	162
6-18	Response surface for Particle size (D90)	165
6-19	Response surface for Entrapment efficiency of Amisulpride	169
6-20	Response surface for Entrapment efficiency of Granisetron	170
6-21	Response surface for Drug loading of amisulpride	174
6-22	Response surface for Drug loading of Granisetron	175
6-23	Response surface for Drug release at 4-hour for Amisulpride	179
6-24	Response surface for Drug release at 4-hour for Granisetron	180
6-25	Selection of drug: polymer ratio and polymer: polymer ratio	181
6-26	Prediction intervals for CQAs of final formulation	181
6-27	Updated risk assessment of Formulation variables	182
6-28	Updated risk assessment of Process variables	182
7-1	List of evaluation techniques for optimized formulation	185
7-2	Particle size distribution of Optimized Formulation	188
7-3	Drug loading and Entrapment efficiency results for optimized formulation	191
7-4	Drug release as per ACC IVRT method (Pure Drug)	192
7-5	Drug release as per ACC IVRT method (Formulation)	193
7-6	Drug release as per real time IVRT method (Pure Drug)	194
7-7	Drug release as per real time IVRT method (Formulation)	194
7-8	Gel diffusion <i>in-vitro</i> release testing method (Pure drug)	196
7-9	Drug release as per Gel Diffusion IVRT method (Formulation)	197
7-10	Drug release kinetics	198
7-11	Mathematical model details for ACC IVRT method	199
7-12	Mathematical model details for RT IVRT method	199
7-13	Stability studies of Optimized Formulation	200
7-14	Drug release of formulations used in building IVIVC	205
7-15	IVIVC Details for Amisulpride	206
7-16	IVIVC Details for Granisetron	207